ACADIA Pharmaceuticals clinical trials we track

Check company identity source

Phase 3 11 trials

TrialDrugs studiedStatusPrimary completion
Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia PsychosisNCT07095465ACP-204Recruiting2029-02Estimated
ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension StudyNCT06194799ACP-204Enrolling by invitation2029-04Estimated
Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi SyndromeNCT06173531CarbetocinCompleted2025-08-19Actual
Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of SchizophreniaNCT04531982PimavanserinCompleted2024-01-25Actual
Extension Study of Pimavanserin in Adult Subjects With Neuropsychiatric Symptoms Related to Neurodegenerative DiseaseNCT03623321PimavanserinCompleted2023-05-05Actual
Open-Label Extension Study of Trofinetide for the Treatment of Girls and Women With Rett SyndromeNCT04279314TrofinetideCompleted2022-08-19Actual
A Safety Study of Pimavanserin in Adult and Elderly Subjects Experiencing Neuropsychiatric Symptoms Related to Neurodegenerative DiseaseNCT03575052PimavanserinCompleted2022-05-06Actual
Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome (LAVENDER™)NCT04181723TrofinetideCompleted2021-10-28Actual
OLE Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi SyndromeNCT06420297CarbetocinTerminated2025-12-19Actual
Extension Study of Pimavanserin for the Adjunctive Treatment of SchizophreniaNCT03121586PimavanserinTerminated2024-04-30Actual
Open-Label Extension Study of Trofinetide for Rett SyndromeNCT04776746trofinetideTerminated2023-06-30Actual

Phase 2 / 3 4 trials

Phase 2 4 trials

Drugs in these trials

Names as written in the registry records.

Latest recorded trial changes

Filters
Clear filters

· 6 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Change from Baseline at Week 12 in caregiver-rated Hyperphagia Questionnaire for Clinical Trials (HQ-CT) score Description: The HQ-CT is a nine-item questionnaire designed to be completed by caregivers of subjects with PWS. It is a revision of the 11-item HPWSQ-R and has been further validated. The Foundation for Prader-Willi Research has made the HQ-CT available for clinical studies in PWS, and it is the consensus instrument within the PWS research community for measuring observable behaviors that stem from subjects' excessive drive to eat. The HQ-CT should be completed by the same caregiver throughout the study. The HQ-CT will be administered to the caregiver by a rater using standardized prompts. The Food Safe Zone should be administered immediately before administration of the HQ-CT. A higher score on the HQ-CT indicates greater severity of hyperphagia. Time frame: Baseline to Week 12. After: Measure: Change From Baseline at Week 12 in Hyperphagia Questionnaire for Clinical Trials (HQ-CT) Score Description: The HQ-CT is a caregiver-reported, 9-item assessment of observable hyperphagia-related behaviors in participants with PWS. The questionnaire is administered to the caregiver by a trained rater using standardized prompts, and the same caregiver is expected to complete the assessment throughout the study whenever possible. Each item is scored from 0 to 4, resulting in a total score ranging from 0 to 36, with higher scores indicating greater severity of hyperphagia. A decrease from baseline reflects improvement, and a reduction of 7.7 points has been identified as a clinically meaningful within-participant improvement. Time frame: Baseline to Week 12.

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 170 participants (planned). After: 175 participants (actual).

Completion date type changed

Before: Estimated. After: Actual.

Primary completion date changed

Before: Oct 2025. After: 19 Aug 2025.

Recruitment status changed

Before: Active not recruiting. After: Completed.

Check registry source

· 5 fields changed

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 160 participants (planned). After: 168 participants (actual).

Completion date type changed

Before: Estimated. After: Actual.

Primary completion date changed

Before: May 2029. After: 19 Dec 2025.

Recruitment status changed

Before: Enrolling by invitation. After: Terminated.

Check registry source

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Change from Baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score at Day 28. After: Measure: Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score at Day 28.

Check registry source